利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

97 条记录 (耗时 0.049 秒)

    PHARMACEUTICAL SOLID DISPERSIONS
    11.
    发明申请
    PHARMACEUTICAL SOLID DISPERSIONS 有权
    药物固体分散体

    公开(公告)号：US20130029965A1

    公开(公告)日：2013-01-31

    申请号：US13610350

    申请日：2012-09-11

    申请人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    发明人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    IPC分类号： A61K31/44 ,  A61K31/404 ,  A61P25/24 ,  A61K31/455

    CPC分类号： A61K9/1635 ,  A61K9/146 ,  A61K9/1652

    摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.

    摘要翻译： 组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。 在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 组合物还包括增加使用环境中药物浓度的浓度增强聚合物。 稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

    Selective ion-complexing media for the removal of metal-ion contaminants from plating baths
    19.
    发明授权
    Selective ion-complexing media for the removal of metal-ion contaminants from plating baths 失效
    用于从电镀浴中去除金属离子污染物的选择性离子络合介质

    公开(公告)号：US4876287A

    公开(公告)日：1989-10-24

    申请号：US929005

    申请日：1986-11-10

    申请人： Walter C. Babcock ,  Dwayne T. Friesen

    发明人： Walter C. Babcock ,  Dwayne T. Friesen

    IPC分类号： C25D21/18

    CPC分类号： C25D21/18

    摘要： Ion-complexing gels are disclosed for the selective removal of metal ions from plating solutions, the gels comprising hydrophobic nonporous polymers plasticized and swollen with either hydroxyoxime or phosphoric acid ester complexing agents. Also disclosed are novel ion-complexing media comprising polymeric microporous anisotropic beads impregnated with the same complexing agents. Copper, zinc and iron contaminants are effectively removed from nickel-plating solutions.

    摘要翻译： 公开了离子络合凝胶用于从电镀溶液中选择性去除金属离子，该凝胶包含用羟基肟或磷酸酯络合剂增塑和溶胀的疏水性无孔聚合物。 还公开了包含用相同络合剂浸渍的聚合物微孔各向异性颗粒的新型离子络合介质。 铜，锌和铁污染物有效地从镀镍溶液中除去。

    Pharmaceutical solid dispersions
    20.
    发明授权
    Pharmaceutical solid dispersions 有权
    药物固体分散体

    公开(公告)号：US08883209B2

    公开(公告)日：2014-11-11

    申请号：US12760393

    申请日：2010-05-25

    申请人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    发明人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    IPC分类号： A61K31/404 ,  A61K9/16 ,  A61K9/14

    CPC分类号： A61K9/1635 ,  A61K9/146 ,  A61K9/1652

    摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.

    摘要翻译： 组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。 本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。 在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 组合物还包括增加使用环境中药物浓度的浓度增强聚合物。 稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。